Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints

(2019) Audrey LEQUEUX et al.   CANCER LETTERS

Hypoxia-induced VISTA promotes the suppressive function of myeloid- derived suppressor cells in the tumor microenvironment

(2019) Jie Deng et al.   Cancer Immunology Research

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy

(2018) Yiliang Li et al.   Frontiers in Immunology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

(2018) Priyamvada Jayaprakash et al.   JOURNAL OF CLINICAL INVESTIGATION

A compendium of proteins that interact with HIF-1α

(2017) Gregg L. Semenza   EXPERIMENTAL CELL RESEARCH

Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies

(2017) Volker H. Haase   EXPERIMENTAL CELL RESEARCH

Immunoregulatory functions of VISTA

(2017) Elizabeth C. Nowak et al.   IMMUNOLOGICAL REVIEWS

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

Cutting Edge: NANOG Activates Autophagy under Hypoxic Stress by Binding to BNIP3L Promoter

(2017) Meriem Hasmim et al.   JOURNAL OF IMMUNOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

(2017) Tianchi Yu et al.   YONSEI MEDICAL JOURNAL

Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells

(2017) Marica Garziera et al.   Journal of Immunology Research

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status

(2016) Yosra Messai et al.   EUROPEAN UROLOGY

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacological targeting of the HIF hydroxylases – A new field in medicine development

(2016) Mun Chiang Chan et al.   MOLECULAR ASPECTS OF MEDICINE

Immune-checkpoint blockade — durable cancer control

(2016) Elizabeth I. Buchbinder et al.   Nature Reviews Clinical Oncology

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

(2016) Caroline Wigerup et al.   PHARMACOLOGY & THERAPEUTICS

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47

(2016) Hui Li et al.   TUMOR BIOLOGY

Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2

(2016) Layale Yaghi et al.   Oncotarget

Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia

(2015) Muhammad Zaeem Noman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

(2015) Mitesh J. Borad et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress

(2015) Meriem Hasmim et al.   Frontiers in Immunology

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

(2015) Emilia Andersson et al.   OncoImmunology

Targeting hypoxia at the forefront of anticancer immune responses

(2015) Muhammad Zaeem Noman et al.   OncoImmunology

CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy

(2014) D. R. Soto-Pantoja et al.   CANCER RESEARCH

Tumor Plasticity Interferes with Anti-Tumor Immunity

(2014) Salem Chouaib et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

(2014) Denise Skrombolas et al.   Expert Review of Clinical Immunology

Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment

(2014) Vinit Kumar et al.   IMMUNOLOGY

Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

(2014) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition

(2014) Darren M. Hutt et al.   PLoS One

New insights into HLA-G mediated tolerance

(2014) G. Amodio et al.   TISSUE ANTIGENS

Autophagic degradation of GZMB/granzyme B

(2013) Elodie Viry et al.   Autophagy

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

(2013) G. Curigliano et al.   CLINICAL CANCER RESEARCH

Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF- 1

(2013) M. Hasmim et al.   JOURNAL OF IMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

(2013) J. Baginska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

(2013) Zachary A. Cooper et al.   OncoImmunology

Hypoxia-induced autophagy

(2012) Muhammad Zaeem Noman et al.   Autophagy

Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells

(2012) M. Z. Noman et al.   CANCER RESEARCH

Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner

(2012) NAOKO YAMADA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

(2012) Gregg L. Semenza   TRENDS IN PHARMACOLOGICAL SCIENCES

HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy

(2012) Wei-Hua Yan   Endocrine Metabolic & Immune Disorders-Drug Targets

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

(2012) Salem Chouaib et al.   Frontiers in Immunology

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

(2011) Jessica ES Bohonowych et al.   BMC CANCER

Blocking Hypoxia-Induced Autophagy in Tumors Restores Cytotoxic T-Cell Activity and Promotes Regression

(2011) M. Z. Noman et al.   CANCER RESEARCH

Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide

(2011) I. B. Barsoum et al.   CANCER RESEARCH

Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells

(2011) Meriem Hasmim et al.   JOURNAL OF IMMUNOLOGY

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1  Expression in an AhR-Independent Fashion

(2010) E. Terzuoli et al.   CANCER RESEARCH

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance?

(2010) Leos Kren et al.   NEUROPATHOLOGY

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Hypoxia-induced autophagy: cell death or cell survival?

(2009) Nathalie M Mazure et al.   CURRENT OPINION IN CELL BIOLOGY

FM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation Status

(2009) Victoria Moreno-Manzano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism

(2009) Kristina M. Cook et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Development of HIF-1 inhibitors for cancer therapy

(2009) Barbara Onnis et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Hypoxia-Induced Autophagy Is Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains

(2009) G. Bellot et al.   MOLECULAR AND CELLULAR BIOLOGY

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

(2009) K. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Beyond the increasing complexity of the immunomodulatory HLA-G molecule

(2008) E. D. Carosella et al.   BLOOD

Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide

(2008) D. R. Siemens et al.   CANCER RESEARCH

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 

(2008) M. Y. Koh et al.   MOLECULAR CANCER THERAPEUTICS

A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth

(2008) L. M. Greenberger et al.   MOLECULAR CANCER THERAPEUTICS

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE